BioCentury

7:00 AM GMT, Jun 21, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

NKTR-102: Phase II data

In an open-label Phase II trial in 68 patients treated with NKTR-102 dosed either every 2 or 3 weeks, both dosing

Read the full 211 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.